Blair McNamara, MD
she/her/hers
Assistant Professor of Obstetrics, Gynecology & Reproductive SciencesCards
About
Research
Publications
2026
Patient Perceptions of a Financial Resource Handout Following Gynecologic Cancer Diagnosis: A Mixed-Methods Study of Feasibility and Patient-Reported Utility
Levine A, Liu C, Harold J, McNamara B, Andikyan V. Patient Perceptions of a Financial Resource Handout Following Gynecologic Cancer Diagnosis: A Mixed-Methods Study of Feasibility and Patient-Reported Utility. Cureus 2026, 18: e104373. PMID: 41913840, PMCID: PMC13033226, DOI: 10.7759/cureus.104373.Peer-Reviewed Original ResearchGynecologic cancer diagnosisMixed-methods studyFinancial toxicityCancer diagnosisInsurance coverageFinancial burdenLevel of insurance coverageLow financial burdenPatient-reported utilitiesResource handoutComprehensive insurance coverageIntervention perceptionsPatients' perceptionsMedical teamMixed-methodsGynecologic malignanciesEmployment disruptionOncological diagnosisFinancial resourcesInterventionStudy of feasibilityHandoutsPatient demographicsTreatment characteristicsParticipants
2025
Association of Platinum-Based Chemotherapy with Survival in Ovarian Carcinosarcoma: A Retrospective Two-Center Cohort Study
Abozenah Y, Erfani H, Haunschild C, Upadhyay A, Greenman M, McNamara B, Papatla K, Clark M, Dottino P, Azodi M, Santin A, Ratner E, Litkouhi B, English D, Altwerger G. Association of Platinum-Based Chemotherapy with Survival in Ovarian Carcinosarcoma: A Retrospective Two-Center Cohort Study. International Journal Of Gynecological Cancer 2025, 104440. PMID: 41535186, DOI: 10.1016/j.ijgc.2025.104440.Peer-Reviewed Original ResearchPlatinum-based chemotherapyPlatinum-based groupNon-platinum-based regimensOvarian carcinosarcomaCytoreductive surgeryOverall survivalRetrospective two-center cohort studyStage III to IV diseaseAdjuvant platinum-based chemotherapyMalignant mixed Mullerian tumorPlatinum-based chemotherapy regimensCox proportional hazards regression model analysisKaplan-Meier survival curvesMedian overall survivalMixed mullerian tumorsOptimal cytoreductive surgeryTwo-center cohort studyStandard chemotherapy regimenAdvanced-stage diseaseLog-rank testRetrospective chart reviewFirst-line approachYale-New Haven HospitalMulti-institutional studyNon-inferiority designA PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, Mcnamara B, Papatla K, Kailasam A, Azodi M, Buza N, Clark M, Hui P, Altwerger G, Dottino P, Ratner E, Bellone S. A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER. International Journal Of Gynecological Cancer 2025, 35: 102143. DOI: 10.1016/j.ijgc.2025.102143.Peer-Reviewed Original ResearchPreclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor
Demirkiran C, Bellone S, Ettorre V, Mansolf M, Hartwich T, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin N, Sethi N, Palmieri L, Coma S, Pachter J, Ottum S, Santin A. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal Of Molecular Sciences 2025, 26: 8924. PMID: 41009492, PMCID: PMC12469703, DOI: 10.3390/ijms26188924.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmFemaleFocal Adhesion Kinase 1FulvestrantHumansMiceMice, SCIDOvarian NeoplasmsProtein Kinase InhibitorsReceptors, EstrogenXenograft Model Antitumor AssaysConceptsPatient-derived tumor xenograftTriple combinationFocal adhesion kinasePreclinical efficacyAromatase inhibitorsClinical evaluationEstrogen receptor (ER)-positiveAcquired resistance to chemotherapyOvarian cancer animal modelEstrogen receptor degrader fulvestrantPatients wild-typeVS-4718Cancer animal modelTumor growth inhibitionLimited treatment optionsResistance to chemotherapyP-ERK levelsFocal adhesion kinase inhibitorMedian survivalRare tumorOvarian carcinomaRecurrence rateTumor xenograftsTreatment optionsFulvestrantAdverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case
Abozenah Y, McNamara B, Greenman M, Daigle E, Mikhaiel J, DiCapua D, Kwan J, Azodi M, Altwerger G. Adverse events beyond the RUBY trial: reporting immunotherapy-associated myocarditis, myositis, and myasthenia gravis in a real-world endometrial cancer case. Gynecologic Oncology Reports 2025, 61: 101950. PMID: 41169950, PMCID: PMC12570088, DOI: 10.1016/j.gore.2025.101950.Peer-Reviewed Original ResearchLife-threatening complicationsMyasthenia gravisImmune checkpoint inhibitor (ICI)-associated myocarditisComplication of ICI therapyPositive acetylcholine receptor antibodyHigh-dose steroidsTreated with carboplatinEndometrial cancer casesAcetylcholine receptor antibodiesDiagnosis of myocarditisElevated creatine kinaseCritical care managementICI therapyElevated troponinBilateral ptosisEndometrial adenocarcinomaReceptor antibodiesCardiac symptomsTherapeutic challengeMultidisciplinary managementRespiratory compromiseCardiac MRIAdverse eventsCancer casesDostarlimabEffective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts
Ettorre V, Demirkiran C, Bellone S, Hartwich T, Greenman M, McNamara B, Sethi N, Palmieri L, Santin A. Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts. Gynecologic Oncology 2025, 201: 195-202. PMID: 40907200, DOI: 10.1016/j.ygyno.2025.08.027.Peer-Reviewed Original ResearchTrophoblast cell surface antigen 2Primary cervical cancer cell linesAntibody-directed cellular cytotoxicityCervical cancer cell linesIn vivo anti-tumor activityAntibody-drug conjugatesCancer cell linesTumor cell deathTumor cellsNon-expressing cell linesCell linesTrophoblast cell surface antigen 2 expressionPreclinical pharmacologyClinical evaluationExpression of trophoblast cell surface antigen 2Cervical cancer mouse modelMedian overall survivalNegative tumor cellsCancer mouse modelCervical cancer patientsTumor growth suppressionCervical carcinoma cell linesCell deathCarcinoma cell linesMarkers of apoptosisPreclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
Santin N, Sethi N, Bellone S, Demirkiran C, Ettorre V, Greenman M, McNamara B, Buza N, Hartwich T, Palmieri L, Lorusso D, Santin A. Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. Cancer Research Communications 2025, 5: 1611-1620. PMID: 40862536, PMCID: PMC12423748, DOI: 10.1158/2767-9764.crc-25-0251.Peer-Reviewed Original ResearchConceptsEndometrial cancer cell linesTrophoblast antigen 2Antibody-dependent cell cytotoxicityAntibody-drug conjugatesEndometrial cancer xenograftsCancer cell linesEndometrial cancerPreclinical activityBystander killingCancer xenograftsCell linesPreclinical evidenceIn vivo activityCell cytotoxicityTargeted treatmentPrimary tumor cell linesBiomarker-targeted therapiesNovel antibody-drug conjugatesControl ADCRecurrent endometrial cancerChromium release assayFlow cytometry-based assayTumor growth inhibitionIn vivoCytometry-based assayUtility of positron emission tomography in preoperative inguinal lymph node assessment for vulvar cancer in the GROINS-VII/sentinel lymph node biopsy era: A single institution retrospective analysis
McNamara B, Abozenah Y, Goreshnik A, Liu C, Altwerger G. Utility of positron emission tomography in preoperative inguinal lymph node assessment for vulvar cancer in the GROINS-VII/sentinel lymph node biopsy era: A single institution retrospective analysis. Gynecologic Oncology 2025, 200: s30. DOI: 10.1016/j.ygyno.2025.04.565.Peer-Reviewed Original ResearchIn vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma
Greenman M, Hartwich T, Demirkiran C, Bellone S, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. In vitro and in vivo activity of datopotamab deruxtecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in uterine and ovarian carcinosarcoma. Gynecologic Oncology 2025, 200: 318. DOI: 10.1016/j.ygyno.2025.04.452.Peer-Reviewed Original ResearchPreclinical efficacy of the estrogen receptor degrader fulvestrant in combination with RAF/MEK clamp avutometinib and FAK inhibitor in low-grade serous ovarian cancer with acquired resistance to chemotherapy and aromatase Inhibitor
Demirkiran C, Bellone S, Ettorre V, Hartwich T, Greenman M, McNamara B, Yang Y, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of the estrogen receptor degrader fulvestrant in combination with RAF/MEK clamp avutometinib and FAK inhibitor in low-grade serous ovarian cancer with acquired resistance to chemotherapy and aromatase Inhibitor. Gynecologic Oncology 2025, 200: 315. DOI: 10.1016/j.ygyno.2025.04.448.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Blair C. McNamara, MD, is an obstetrician-gynecologist specializing in gynecologic oncology. She focuses on diagnosing and treating cancers of the female reproductive system, with particular attention to providing comprehensive care for patients facing these conditions. She offers individually tailored treatments that range from surgical interventions to minimally invasive procedures.
As an assistant professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, Dr. McNamara conducts research aimed at understanding rare cervical cancers and developing new therapeutic strategies.
Dr. McNamara received her medical degree from Yale School of Medicine, and completed her residency in obstetrics and gynecology at the University of California San Francisco.
Clinical Specialties
Gynecologic Oncology
Board Certifications
Obstetrics & Gynecology
- Certification Organization
- AB of Obstetrics & Gynecology
- Original Certification Date
- 2025
News
News
- January 06, 2026Source: Yale News
Office Hours: Getting to Know… Blair McNamara
- June 23, 2025
2025 OB/GYN Research and Graduation Day
- March 20, 2025
Smilow Cancer Hospital Gynecologic Oncology Expertise in Fairfield County
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
Get In Touch
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.